Clinical Trial Detail

NCT ID NCT01538680
Title Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Recruitment No longer available
Gender both
Phase Phase III
Variant Requirements no
Sponsors Bayer
Indications

rectum adenocarcinoma

colon adenocarcinoma

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.